Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Receivables (2021 - 2025)

Apellis Pharmaceuticals has reported Change in Receivables over the past 5 years, most recently at $20.7 million for Q4 2025.

  • Quarterly results put Change in Receivables at $20.7 million for Q4 2025, up 246.78% from a year ago — trailing twelve months through Dec 2025 was $101.3 million (up 73.17% YoY), and the annual figure for FY2025 was $101.3 million, up 73.17%.
  • Change in Receivables for Q4 2025 was $20.7 million at Apellis Pharmaceuticals, down from $131.4 million in the prior quarter.
  • Over the last five years, Change in Receivables for APLS hit a ceiling of $131.4 million in Q3 2025 and a floor of -$29.7 million in Q1 2025.
  • Median Change in Receivables over the past 5 years was $4.7 million (2021), compared with a mean of $20.3 million.
  • Biggest five-year swings in Change in Receivables: soared 10284.38% in 2023 and later crashed 157.74% in 2025.
  • Apellis Pharmaceuticals' Change in Receivables stood at $7.5 million in 2021, then plummeted by 104.88% to -$365000.0 in 2022, then soared by 10284.38% to $37.2 million in 2023, then crashed by 137.89% to -$14.1 million in 2024, then skyrocketed by 246.78% to $20.7 million in 2025.
  • The last three reported values for Change in Receivables were $20.7 million (Q4 2025), $131.4 million (Q3 2025), and -$21.1 million (Q2 2025) per Business Quant data.